Tevimbra (Tislelizumab-jsgr) – NSCLC | DengYueMed

Tevimbra Application Scope

Tevimbra is a humanized anti‑PD‑1 monoclonal antibody used to treat advanced esophageal and gastric cancers.

Tevimbra Characteristics

• Ingredients: Tislelizumab-jsgr

• Properties:

  • Clear to slightly opalescent, colorless to pale yellow solution

  • Single‑dose intravenous infusion vial (100 mg/10 mL; 10 mg/mL)

• Packaging Specification: 100 mg in 10 mL per single‑use vial

• Storage: Inspect visually; do not use if discolored or infused with particles

• Expiry Date: Refer to the vial label and pack–specific expiration

• Executive Standard: Conforms to FDA and EMA Summary of Product Characteristics (SmPC)

• Approval Number: FDA (NDA 761417), EMA (CP Code VR/0000269138)

• Date of Revision: FDA label updated mid‑2025, EMA SmPC revised June 2, 2025

• Manufacturer: Developed and marketed by BeiGene (BeOne Medicines Ireland Limited)

Guidelines for the Use of Tevimbra

• Dosage and Administration:

  • Standard dose: 200 mg IV infusion every 3 weeks for esophageal or gastric cancers

  • Administer before chemotherapy on the same day

  • Infusion duration: 30–60 minutes;

  • If tolerated, subsequent infusions may be sped up to 30 minutes

• Adverse Reactions:

  • Common:

    • fatigue, nausea, anorexia, anemia, neutropenia, peripheral neuropathy

    • diarrhea, mucositis, liver enzyme elevations, cough, pyrexia

• Contraindications: None absolute, but avoid live vaccines during therapy

• Precautions:

  • Monitor for immune-mediated events: pneumonitis, colitis, hepatitis, nephritis, endocrinopathies

  • Use birth control during and for 4 months post-treatment; avoid while pregnant or breastfeeding

Tevimbra Interactions

• Drug Interactions:

  • Avoid mixing with other IV drugs in the same line.

  • Flush the line before and after infusion

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.